A Multicenter Study to Assess Response to Influenza Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab
Status:
Recruiting
Trial end date:
2022-07-06
Target enrollment:
Participant gender:
Summary
To assess whether participants treated with ofatumumab 20 mg subcutaneous (s.c.) administered
once every 4 weeks (q4) can mount an adequate immune response to inactivated influenza
vaccine as measured by humoral responses compared to participants on an iDMT.